Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery
Status:
Completed
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
In this randomized clinical trial, patients with undergoing open heart valve surgery will be
enrolled into the study. Participants will be divided into two groups based on the priming
solution type. The first group will receive hydroxyethyl starch (HES) 130/0.4 additive to
ringer lactate (RL) and the second group will be given only RL as priming solution. All
patients will be observed closely during postoperative days. Through follow up,
bleeding/coagulopathy, renal function, hepatic function, and cerebral oxygenation will be
recorded in both groups.